Growing evidence indicates that Alzheimer's disease (AD) is associated with profound changes in the metabolism of lipids and that these changes, in turn, may be responsible for the perturbation of molecular pathways underlying synaptic dysfunction and cognitive decline. In this proposal, we investigate the link between amyloid beta (Abeta) and phosphatidic acid (PtdOH), a key signaling phospholipid that controls multiple cellular processes. We have found that a treatment of cultured neurons with soluble Abeta oligomers increases PtdOH levels without marked effects on cell viability. Because the phospholipase D (PLD) pathway is a primary source of PtdOH, we have focused on this family of lipid enzymes. Accordingly, treatment of cultured neurons and neuroblastoma cells with Abeta42 oligomers as well as expression ofthe Swedish mutant of APP (swAPP) lead to a significant increase in PLD activity. To genetically test for the relevance of the PLD pathway in AD, we have generated mice harboring a conditional deletion of the Pld2 gene. Our preliminary results indicate that Pld2 ablation suppresses the synaptic-impairing action of Abeta in hippocampal slices, suggesting that it confers protection against the cytotoxic petide. Furthermore, Pld2 knockout cortical neurons secrete lower amounts of AP40 and AP42, indicating that PLD2 also modulates the processing of amyloid precursor protein (APP). Stirkingly, our behavioral analysis shows that contextual learning is improved in a transgenic mouse model of AD (swAPP) that either lacks one copy (swAPP/Pld2+/-) or two copies (swAPP/Pld2-/-) of Pld2. Altogether, our findings suggest a hypothesis whereby PtdOH dyshomeostasis may be a key manifestation in AD, where it may account for aberrant processing of APP and participate to the neurotoxic effects of Abeta in neurons.
The specific aims ofthis application will be: (i) to further characterize biochemical changes in PtdOH metabolism and PLD activity downstream of Abeta and swAPP expression;(ii) to investigate the processing of APP upon ablation ofthe Pld2 gene in cultured neurons as well as in vivo;and (iii) to test whether ablation of Pld2 ameliorates synaptic dysfunction and learning deficits in the swAPP mouse model.

Public Health Relevance

AD is the most common form of late onset dementia. Because Amyloid Precursor Protein plays a fundamental role in this disorder, understanding the molecular mechanisms, and lipid changes in particular, which regulate the processing of this protein as well as signaling downstream of amyloid beta is of critical importance to prevent AD-linked synaptic dysfunction and cognitive decline.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG008702-23
Application #
8573795
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4)
Project Start
1997-06-15
Project End
2015-05-31
Budget Start
2012-06-01
Budget End
2013-05-31
Support Year
23
Fiscal Year
2012
Total Cost
$218,640
Indirect Cost
$76,676
Name
Columbia University (N.Y.)
Department
Type
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872
Winawer, Melodie R; Griffin, Nicole G; Samanamud, Jorge et al. (2018) Somatic SLC35A2 variants in the brain are associated with intractable neocortical epilepsy. Ann Neurol 83:1133-1146
Tse, Kai-Hei; Cheng, Aifang; Ma, Fulin et al. (2018) DNA damage-associated oligodendrocyte degeneration precedes amyloid pathology and contributes to Alzheimer's disease and dementia. Alzheimers Dement 14:664-679
Schaffert, Jeff; LoBue, Christian; White, Charles L et al. (2018) Traumatic brain injury history is associated with an earlier age of dementia onset in autopsy-confirmed Alzheimer's disease. Neuropsychology 32:410-416
Qureshi, Yasir H; Patel, Vivek M; Berman, Diego E et al. (2018) An Alzheimer's Disease-Linked Loss-of-Function CLN5 Variant Impairs Cathepsin D Maturation, Consistent with a Retromer Trafficking Defect. Mol Cell Biol 38:
Reitz, Christiane (2018) Retromer Dysfunction and Neurodegenerative Disease. Curr Genomics 19:279-288
Davis, Jeremy J (2018) Performance validity in older adults: Observed versus predicted false positive rates in relation to number of tests administered. J Clin Exp Neuropsychol 40:1013-1021
Tariciotti, Leonardo; Casadei, Matthew; Honig, Lawrence S et al. (2018) Clinical Experience with Cerebrospinal Fluid A?42, Total and Phosphorylated Tau in the Evaluation of 1,016 Individuals for Suspected Dementia. J Alzheimers Dis 65:1417-1425
Masucci, Michael D; Lister, Amanda; Corcoran, Cheryl M et al. (2018) Motor Dysfunction as a Risk Factor for Conversion to Psychosis Independent of Medication Use in a Psychosis-Risk Cohort. J Nerv Ment Dis 206:356-361
Crum, Jana; Wilson, Jeffrey; Sabbagh, Marwan (2018) Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer's dementia? Alzheimers Res Ther 10:104

Showing the most recent 10 out of 640 publications